GlobeNewswire Inc.··Pharvaris N.V.Pharvaris Raises $115M to Advance Rare Disease Pipeline
Pharvaris raises $115M through 3.87M share offering at $29.68 per share to advance oral angioedema treatments; Phase 3 data expected Q3 2026.
PHVSPhase 3 clinical trialFDA approval